Back to Browse Journals » HIV/AIDS - Research and Palliative Care » Volume 4

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Authors Lee JSF, Calmy A, Andrieux-Meyer I, Ford N

Published Date January 2012 Volume 2012:4 Pages 5—15


Received 17 October 2011, Accepted 28 November 2011, Published 12 January 2012

Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,3
1Médecins Sans Frontières, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa

Abstract: Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug–drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.

Keywords: elvitegravir, efficacy, safety, resistance, resource-limited settings

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China

Peng B, Yang XW, Zhang Y, Dai JH, Liang H, Zou YF, Luo JK, Peng HB, Zhong XN, Huang AL

HIV/AIDS - Research and Palliative Care 2012, 4:149-158

Published Date: 24 September 2012

Quality of life of people living with HIV and AIDS and antiretroviral therapy

Oguntibeju OO

HIV/AIDS - Research and Palliative Care 2012, 4:117-124

Published Date: 6 August 2012

Cultural differences in acceptability of a vaginal microbicide: a comparison between potential users from Nashville, Tennessee, USA, and Kafue and Mumbwa, Zambia

Montgomery Rice V, Maimbolwa MC, Nkandu EM, Fleming Hampton J, Lee JE, Hildreth JEK

HIV/AIDS - Research and Palliative Care 2012, 4:73-80

Published Date: 9 May 2012

Cross-cultural adaptation and validation of the self-reporting questionnaire among HIV+ individuals in a rural ART program in southern Uganda

Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, Katabira E, Musisi S, Nachega JB, Bass JK

HIV/AIDS - Research and Palliative Care 2012, 4:51-60

Published Date: 12 April 2012

The use of preexposure treatments for HIV prophylaxis

Majid A, Redfield RR, Gilliam BL

HIV/AIDS - Research and Palliative Care 2012, 4:17-28

Published Date: 3 February 2012

HIV infection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa

Mamadou S, Ide M, Maazou ARA, Aoula B, Labo S, Bozari M

HIV/AIDS - Research and Palliative Care 2012, 4:1-4

Published Date: 21 December 2011